Status:
UNKNOWN
Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
Lead Sponsor:
Retina Associates of Kentucky
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Ocular Histoplasmosis Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.
Detailed Description
Patients will be evaluated monthly for one year. Participants will be assigned to one of two groups: Group A will receive 3 monthly injections of ranibizumab followed by an as needed injection throu...
Eligibility Criteria
Inclusion
- age 18 or over
- active choroidal neovascularization secondary to ocular histoplasmosis
- Visual acuity between 20/25 and 20/400
Exclusion
- pregnancy or intent to become pregnant within the next 12 months
- nursing an infant
- premenopausal women not using contraception
- prior treatment with subfoveal thermal laser
- allergy to sodium fluorescein simultaneous participation in another investigation or trial
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00955630
Start Date
August 1 2009
Last Update
August 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Associates of Kentucky
Lexington, Kentucky, United States, 40509